Arthritis Rheumatol by Plantinga, Laura C. et al.
Sociodemographic and Geographic Predictors of Quality of Care 
in United States Patients With End-Stage Renal Disease Due to 
Lupus Nephritis
Laura C. Plantinga1, Cristina Drenkard1, Rachel E. Patzer2, Mitchel Klein1, Michael R. 
Kramer1, Stephen Pastan2, S. Sam Lim1, and William M. McClellan1
1Laura C. Plantinga, PhD, Cristina Drenkard, MD, PhD, Mitchel Klein, PhD, Michael R. Kramer, 
PhD, S. Sam Lim, MD, MPH, William M. McClellan, MD, MPH: Emory University, Atlanta, Georgia
2Rachel E. Patzer, PhD, MPH, Stephen Pastan, MD: Emory University and Emory Transplant 
Center, Emory Healthcare, Atlanta, Georgia
Abstract
Objective—To describe end-stage renal disease (ESRD) quality of care (receipt of pre-ESRD 
nephrology care, access to kidney transplantation, and placement of permanent vascular access for 
dialysis) in US patients with ESRD due to lupus nephritis (LN-ESRD) and to examine whether 
quality measures differ by patient sociodemographic characteristics or US region.
Methods—National surveillance data on patients in the US in whom treatment for LN-ESRD 
was initiated between July 2005 and September 2011 (n = 6,594) were analyzed. Odds ratios 
(ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were determined for each 
quality measure, according to sociodemographic factors and US region.
Results—Overall, 71% of the patients received nephrology care prior to ESRD. Black and 
Hispanic patients were less likely than white patients to receive pre-ESRD care (OR 0.73 [95% CI 
0.63–0.85] and OR 0.73 [95% CI 0.60–0.88], respectively) and to be placed on the kidney 
transplant waitlist within the first year after the start of ESRD (HR 0.78 [95% CI 0.68–0.91] and 
HR 0.82 [95% CI 0.68–0.98], respectively). Those with Medicaid (HR 0.51 [95% CI 0.44–0.58]) 
or no insurance (HR 0.36 [95% CI 0.29–0.44]) were less likely than those with private insurance 
to be placed on the waitlist. Only 24% had a permanent vascular access, and placement was even 
less likely among the uninsured (OR 0.62 [95% CI 0.49–0.79]). ESRD quality-of-care measures 
varied 2–3-fold across regions of the US, with patients in the Northeast and Northwest generally 
having higher probabilities of adequate care.
Address correspondence to Laura C. Plantinga, PhD, Division of Renal Medicine, Emory University, 5105 Woodruff Memorial 
Building, 101 Woodruff Circle, Atlanta, GA 30322. laura. plantinga@emory.edu. 
Dr. Drenkard has received speaking fees from Questcor Pharmaceuticals (less than $10,000).
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the 
final version to be published. Dr. Plantinga had full access to all of the data in the study and takes responsibility for the integrity of the 
data and the accuracy of the data analysis.
Study conception and design. Plantinga, Drenkard, Patzer, Lim, McClellan.
Acquisition of data. Plantinga, Lim.
Analysis and interpretation of data. Plantinga, Drenkard, Patzer, Klein, Kramer, Pastan, Lim, McClellan.
HHS Public Access
Author manuscript
Arthritis Rheumatol. Author manuscript; available in PMC 2017 March 07.
Published in final edited form as:













Conclusion—LN-ESRD patients have suboptimal ESRD care, particularly with regard to 
placement of dialysis vascular access. Minority race/ethnicity and lack of private insurance are 
associated with inadequate ESRD care. Further studies are warranted to examine multilevel 
barriers to, and develop targeted interventions to improve delivery of, care among patients with 
LN-ESRD.
The Centers for Medicare & Medicaid Services (CMS), which covers end-stage renal 
disease (ESRD) care for all eligible patients in the US, is highly invested in promoting 
quality of care, including mandated pay-for-performance (1). Through its 18 ESRD 
Networks (www.esrdnetworks.org), CMS regionally monitors ESRD care and facilitates 
quality improvement. Quality of ESRD care is also a priority of Healthy People 2020 
(www.healthypeople.gov) (2), supported by evidence that receipt of pre-ESRD care (3–11), 
access to kidney transplantation (12–17), and permanent vascular accesses for dialysis, 
which include arteriovenous fistulae (AVFs) and grafts (18–25), are all associated with better 
patient outcomes and lower health care costs. Since 2005, CMS has collected information 
addressing these objectives on all patients with incident ESRD via the CMS Medical 
Evidence Report (CMS Form 2728), which is completed for all patients at the start of ESRD 
treatment. The data have been used to describe not only the translation of these quality-of-
care measures, but also disparities in the success of this translation. In the overall ESRD 
population, black race, lower socioeconomic status, and US region (particularly, the 
Southeast) have all been associated with lower attainment of the goals of pre-ESRD care 
(26–28), being informed of the transplant option (29), placement on the national deceased 
donor kidney waitlist (17,30,31), and permanent vascular access (32,33).
With the exception of placement on the kidney transplant list (34,35), these markers of the 
quality of ESRD care remain relatively unexamined in patients with systemic lupus 
erythematosus (SLE) and ESRD secondary to lupus nephritis (LN-ESRD). Investigation into 
the translation of these measures in LN-ESRD patients is important because guidelines to 
address the preparation for ESRD are generally lacking for rheumatologists (36), who could 
partner with nephrologists and other providers to improve ESRD care among these patients. 
Identification of sociodemographic and geographic disparities in quality of ESRD care 
among SLE patients, as seen in LN care (37), could potentially guide the development of 
regional interventions targeted to patients most likely to receive inadequate ESRD care. Our 
aim in the present study was to describe the translation of ESRD quality-of-care measures 
among US patients with LN-ESRD and to estimate the associations of sociodemographic 
and geographic factors with successful translation of quality-of-care measures in these 
patients.
PATIENTS AND METHODS
Study population and data sources
The primary data source for this study was the United States Renal Data System (USRDS). 
Data from the CMS-2728, completed on all treated US patients with incident ESRD, were 
obtained from the USRDS (17). A total of 6,594 patients with incident LN-ESRD in whom 
treatment was initiated between July 1, 2005 and September 30, 2011 and for whom there 
were data from the most recent (2005) version of the CMS-2728 were identified via a listing 
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of “lupus erythematosus (SLE nephritis)” (International Classification of Diseases, Ninth 
Revision code 710.0) as the primary attributed cause of ESRD on the CMS-2728; this is the 
method of identification used in most recent population studies of LN-ESRD incidence 
(34,35). Of these patients, 655 (9.9%) had unknown pre-ESRD nephrology care status and 
were excluded from that analysis (Figure 1). For analysis of measures of access to 
transplantation (informed of transplant options, placement on the kidney transplant waitlist), 
patients who underwent preemptive transplantation (n = 292 [4.4%]) or were preemptively 
placed on the waitlist (n = 424 [6.4%]) or who were age ≥70 years (n = 259 [3.9%]) were 
excluded from the 6,594 LN-ESRD patients, leaving 5,619 (85.2%) for analysis. For 
analyses of permanent vascular access, those with preemptive transplants (n = 292 [4.4%]) 
and those treated with peritoneal dialysis (n = 678 [10.3%]) were excluded, leaving 5,624 
(85.3%) (Figure 1).
Data on primary attributed cause of ESRD, quality-of-care measures (nephrology care prior 
to ESRD, informed of transplant options, and vascular access at the time of first dialysis), 
race/ethnicity, insurance status, and clinical factors were all obtained from the CMS-2728 
through the USRDS. The United Network for Organ Sharing (UNOS) maintains the national 
deceased donor kidney waitlist and provides these data to the USRDS. Data on 
characteristics of the patients’ residential neighborhoods, as defined by patient 5-digit ZIP 
code tabulation area (ZCTA), were obtained from the 2007–2011 American Community 
Survey (www.census.gov/acs/www/) via the Minnesota Population Center (www.nghis.org) 
(38) and linked by patient ZIP code at the start of ESRD to the USRDS data.
Study variables
Sociodemographics and geography—Individual sociodemographic exposures of 
interest included race/ethnicity (defined as white, black, Hispanic, and other) and insurance 
prior to ESRD (defined as private, Medicaid, none, or other). Due to the relative lack of 
individual-level information on socioeconomic status and the potential for neighborhood 
effects independent of individual socioeconomic status, we also examined aggregate 
residential ZCTA-level data on the percentage of residents reporting black race, the 
percentage of residents reporting Hispanic ethnicity, the percentage of residents who had 
dropped out of high school (residents age ≥25 years without a high school degree or 
equivalent), and the percentage of residents who were poor (households living below 100% 
of the federal poverty threshold) from the American Community Survey. Finally, due to the 
regional implementation of CMS quality-of-care measures via the 18 ESRD Networks, the 
ESRD Network in which the patient received treatment was included as a geographic 
exposure of interest.
Quality-of-care measures—The outcomes of interest were ESRD quality-of-care 
measures, specifically 1) pre-ESRD nephrology care, 2) access to transplant, including being 
informed of transplant options at the start of ESRD and being placed on the national 
deceased donor kidney transplant waitlist (“kidney transplant waitlisting”), and 3) permanent 
vascular access placement prior to the start of dialysis. Pre-ESRD nephrology care was 
defined by an answer of “yes” to item 18b on the CMS-2728: “Prior to ESRD therapy was 
the patient under the care of a nephrologist?” Whether patients were informed of transplant 
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option was defined by a “yes” answer to CMS-2728 item 26: “Has patient been informed of 
kidney transplant options?” Date of placement on the deceased donor transplant waitlist was 
determined from UNOS data and used to calculate time to transplant waitlisting (from date 
of first ESRD service to date of placement on the waitlist). Censoring occurred at death (of 
3,552 patients who were not waitlisted, 1,093 [30.8%] died, 562 [15.8%] within the first 
year) or at the end of followup (September 30, 2011; median followup 1.3 years). Finally, 
vascular access was determined from CMS-2728 item 18d: “What access was used on first 
outpatient dialysis?” with possible responses of “AVF,” “graft,” “catheter,” and “other” and 
2 additional prompts for maturing permanent accesses in place (“Is maturing AVF present?” 
and “Is maturing graft present?”). Permanent vascular access was defined as AVF or graft 
used or in place on first dialysis.
Other variables—Data on sex and age at incident LN-ESRD were obtained from the 
USRDS patient demographics file. Smoking status, body mass index, presence of comorbid 
conditions, and serum albumin and hemoglobin levels at the start of ESRD were obtained 
from the CMS-2728.
Statistical analysis
Patient characteristics including sociodemographics and ESRD Network were summarized 
for all LN-ESRD patients, and quality-of-care measures were summarized and compared 
across sociodemographic characteristics and region within appropriate study populations. 
Odds ratios (ORs) and 95% confidence intervals (95% CIs) for the associations between 
dichotomous outcomes (pre-ESRD nephrology care, informed of transplant options, and 
permanent vascular access placement) were estimated using multivariable logistic regression 
models. For transplant waitlisting, incidence rates were calculated as the number of patients 
placed on the kidney transplant waitlist per person-time, which included all time contributed 
by all patients from start of ESRD to waitlisting, death, or last date of followup. Violations 
of Cox proportional hazards assumptions were assessed by tests of Schoenfeld residuals and 
examination of log–log plots. Hazard ratios (HRs) and 95% CIs were obtained using 
multivariable Cox proportional hazards models run over the entire followup period as well as 
using Heaviside functions to split the followup time. To avoid the arbitrary choice of referent 
group among US regions, adjusted probabilities and incidence rates were also estimated 
using marginal post-estimation of logistic and Poisson models and mapped using 
approximate quartiles or medians of the distribution, as appropriate. Factors that were 
associated with both sociodemographic predictors and quality-of-care measures and were 
not thought a priori to be mediators of the association were considered potential 
confounders.
Clustering at the ZCTA level (multiple LN-ESRD patients in a ZCTA) was minimal, with 
85% of patients living in ZCTAs with only 1 patient (46%), 2 patients (25%), or 3 patients 
(14%). Sensitivity analyses at 2 extremes—i.e., with all missing values on pre-ESRD care 
either assigned “yes” or assigned “no”—were performed and the results compared to the 
primary results, to determine how much the estimates might be biased if missing data were 
differential with respect to delivery of pre-ESRD care. Stata version 13 (StataCorp) was used 
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for all analyses, and the threshold for statistical significance was set at α = 0.05. Mapping 
was performed using ArcGIS version 10.1 (Esri).
RESULTS
Characteristics of the study population
The mean age of the 6,594 US patients with incident LN-ESRD was 40 years. Most were 
female (although, disproportionate to the overall SLE population, nearly 19% were male), 
and half were black (Table 1). One-third of these patients had Medicaid and >10% were 
uninsured at the start of ESRD. In patients’ residential ZCTAs, the median percentages of 
residents who were black, who had dropped out of high school, and who were living in 
poverty were 14%, 17%, and 17%, respectively (Table 1). The most common comorbidity 
among these young patients was hypertension, followed by cardiovascular disease including 
pericarditis (Table 1). The percentages of all LN-ESRD patients treated within ESRD 
Networks ranged from ~2% (Network 16, Northwest) to >10% (Networks 6 and 14, 
Southeast and Texas). The group of 655 patients with missing information on pre-ESRD 
care (excluded from pre-ESRD care analyses) was similar to those included in terms of most 
patient characteristics, except that those with missing information were more likely to be 
black (53.1% versus 49.3%) or Hispanic (20.3% versus 17.4%; P = 0.003) and to have 
Medicaid (36.3% versus 32.4%) or no insurance (15.6% versus 11.1%; P < 0.001) and less 
likely to have a body mass index of ≥35 kg/m2 (9.7% versus 12.9%; P = 0.02).
Association of social predictors with quality-of-care measures
Pre-ESRD care—Overall, 71.1% of the US patients with LN-ESRD received pre-ESRD 
nephrology care (Table 2), and the percentage did not differ by incidence year (P = 0.47 
[data not shown]). After adjustment for potential confounders, black and Hispanic LN-
ESRD patients were found to be 27% less likely to have received pre-ESRD care than their 
white counterparts, and those with Medicaid and those with no insurance prior to ESRD 
development were 36% and 74% less likely to receive this care, relative to those with private 
insurance (Table 2). Results were not substantially different when models were further 
adjusted for hemoglobin or albumin levels (data not shown). Of the 5,939 patients with 
information on pre-ESRD care, 26 (0.4%) were potentially misclassified in that the patient 
either had a preemptive transplant or was preemptively waitlisted; redefining these 
individuals as having pre-ESRD care did not change the results (data not shown).
After adjustment, LN-ESRD patients living in ZCTAs in which above-median percentages 
of residents were black, Hispanic, high school dropouts, and poor were 5%, 17%, 11%, and 
16% less likely, respectively, to have had pre-ESRD care, although only the association with 
poverty was statistically significant (Table 2). Sensitivity analyses showed that associations 
with imputed missing values of pre-ESRD care were similar in terms of magnitude and 
statistical significance, ranging from 0.72 to 0.77 for black versus white race, 0.70 to 0.78 
for Hispanic versus white, 0.72 to 0.80 for Medicaid versus private insurance, and 0.28 to 
0.31 for no insurance versus private insurance.
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Access to transplant—Overall, 84.8% of LN-ESRD patients had been informed of 
transplant options at the start of ESRD, with 83.6% and 87.8% being informed in incidence 
years 2006 and 2010, respectively (P = 0.05 for time trend). Relative to having private 
insurance at the start of ESRD, having Medicaid, no insurance, or other types of insurance 
was associated with a 32–39% decreased likelihood of having been informed of transplant 
options, after adjustment for potential confounders (Table 2). Race/ethnicity and ZCTA-level 
proportion of residents of black race or living in poverty were not associated with having 
been informed of transplant options. ZCTA-level education (percentage who dropped out of 
high school) was associated with a 13% decreased likelihood of being informed of transplant 
options, although the association was not statistically significant (Table 2).
Rates of transplant waitlisting were 206 per 1,000 patient-years overall, ranging from 177 to 
263 per 1,000 patient-years in 2006 and 2010, respectively (P < 0.001 for time trend). Tests 
of the proportional hazards assumption indicated potential violations (P < 0.05 for all 
sociodemographic predictors). Examination of log–log plots did not reveal substantial 
departures from parallel except at around the end of the first year, when data were sparse but 
suggested potential crossing of the curves; thus, followup split at 1 year as well as overall 
was utilized. Adjusted hazards of kidney transplant waitlisting during followup were 
substantially lower among LN-ESRD patients with Medicaid, no insurance, or other 
insurance, relative to those with private insurance at ESRD development (48%, 51%, and 
30% lower, respectively); results were similar in the first year of ESRD and after the first 
year of ESRD (Table 3). Black and Hispanic LN-ESRD patients, respectively, were 22% and 
18% less likely to be waitlisted than white LN-ESRD patients, but only within the first year 
of ESRD. LN-ESRD patients living in ZCTAs with lower educational attainment and more 
poverty were less likely to be waitlisted (25% and 35%, respectively), but this was also the 
case only within the first year of ESRD (Table 3).
Findings of analyses including both waitlisting and living donor transplants without prior 
waitlisting (n = 69), with censoring at the time of transplant, were slightly further from the 
null but were not substantially different from results reported in Table 3 (data not shown). 
Results were similar when only the patients who survived 1 year were included, except that 
ZCTA-level black race remained statistically significantly associated with lower likelihood 
of waitlisting in the first year of ESRD, after adjustment (HR 0.79 [95% CI 0.69–0.90]).
Permanent hemodialysis vascular access—Only approximately one-quarter of LN-
ESRD patients who received hemodialysis as the initial ESRD treatment had a fistula or 
graft used or in place on first dialysis (Table 2), with no differences over time (P = 0.45). 
The percentage of LN-ESRD patients with a permanent vascular access did not differ by 
early transplant status (27.2% of those undergoing transplant within 1 year versus 24.3% of 
those not undergoing transplant within 1 year; P = 0.32). The likelihood of having a 
permanent vascular access did not differ by race/ethnicity or ZCTA-level 
sociodemographics. The likelihood was also equivalent among those with private insurance, 
Medicaid, or other insurance, but having no insurance was associated with a 38% reduced 
likelihood of permanent vascular access among LN-ESRD patients (Table 2).
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Association of ESRD Network with quality-of-care measures
Pre-ESRD care—Receipt of pre-ESRD nephrology care among LN-ESRD patients 
differed substantially by ESRD Network (Table 4). Age-, sex-, race/ethnicity- and insurance-
adjusted probabilities of pre-ESRD care ranged from 0.66 (95% CI 0.60–0.71) in Illinois 
(Network 10) to 0.81 (95% CI, 0.74–0.87) in New England (Network 1) (Figure 2A).
Access to transplant—The likelihood of being informed of transplant options did not 
differ by ESRD Network (Table 4), and the range of adjusted probabilities was small (Figure 
2B), from 0.81 (95% CI 0.74–0.880 (Network 16, Northwest) to 0.90 (95% CI 0.85–0.93) 
(Network 3, New Jersey). However, there was some evidence that waitlisting for transplant 
in LN-ESRD patients, particularly in the first year of ESRD, does differ by ESRD Network 
(Table 4). Age-, sex-, race/ethnicity-, and insurance-adjusted incidence of kidney transplant 
waitlisting per 1,000 patient-years over the entire period varied by >2.5-fold, from 148 (95% 
CI 121–175) (Network 7, Florida) to 373 (95% CI 307–440) (Network 17, Northern 
California and Hawaii) (Figure 2C).
Permanent vascular access—There was substantial, statistically significant ESRD 
Network–level variation in likelihood of permanent vascular access (Table 4). Age-, sex-, 
race/ethnicity-, and insurance-adjusted probabilities of permanent vascular access used or in 
place at first dialysis ranged from 0.17 (95% CI 0.12–0.21) (Network 10) to 0.33 (95% CI 
0.24–0.41) (Network 16) (Figure 2D).
DISCUSSION
Despite multiple national and regional quality-of-care initiatives and incentives aimed at 
improving care in the overall ESRD population (1,2,32), we found that, among patients with 
LN-ESRD, care remains suboptimal, particularly with respect to permanent vascular access 
placement. Nearly one-third of patients with LN-ESRD had received no pre-ESRD 
nephrology care at the start of ESRD treatment, similar to the overall ESRD population, in 
whom 34–35% had not received this care in 2007–2010 (17). While in some of these 
patients ESRD may have been the earliest manifestation of SLE, precluding pre-ESRD care, 
it is likely that most were not referred to a nephrologist in a timely manner, putting them at 
risk for poor outcomes (39). Most potentially eligible LN-ESRD patients (85%) were 
reported to be informed of transplant options at the start of ESRD, higher than the 
percentage in the overall ESRD population (70% in 2005–2007) (29), but the incidence of 
subsequent waitlisting was only ~20% per year. However, both the proportion of LN-ESRD 
patients who were informed of transplant options and the proportion who were on the 
transplant waitlist increased over the study period, and the proportion on the waitlist was 
much higher than in the general ESRD population, in whom only 11–12% were waitlisted 
during the first year in 2007–2010 (17). Notably, fewer than one-quarter of LN-ESRD 
patients treated with hemodialysis had a permanent vascular access in place at the start of 
treatment, versus 35–36% in 2007–2010 in the overall ESRD population (17). This 
percentage was higher among those who underwent transplantation early, suggesting that 
provider decisions to forego vascular access surgery in patients expected to receive a 
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transplant imminently do not explain the low likelihood of permanent vascular access 
placement among LN-ESRD patients.
Our findings also indicate that there are substantial sociodemographic and regional 
disparities in the translation of quality-of-care measures related to pre-ESRD care, access to 
transplant, and placement of permanent vascular access among LN-ESRD patients. Black 
and Hispanic patients were less likely to have had pre-ESRD nephrology care and permanent 
vascular accesses than their white counterparts, as in the overall ESRD population (28,32), 
although differences in permanent vascular access by race/ethnicity were not statistically 
significant after adjustment for other sociodemographic and clinical factors. Black race and 
Hispanic ethnicity were also associated with lower likelihood of kidney transplant 
waitlisting in the first year of ESRD treatment relative to white race, similar to patterns in 
the overall ESRD population (30,31,40). Faster progression of lupus nephritis (41,42) and 
reduced engagement with the health care system among minority LN-ESRD patients may 
contribute to racial and ethnic disparities in pre-ESRD nephrology care and early transplant 
waitlisting in this population.
While patient race/ethnicity was not associated with being informed of transplant options or, 
after the first year, with waitlisting, these apparent equivalencies may not be sufficient to 
close racial and ethnic gaps in kidney transplantation created by the early lag in wait-listing, 
relative to white patients. Further, how well patients are actually informed of transplant 
options—and whether this translates to usable knowledge of the options—may differ by 
race/ethnicity. Among patients who are not informed, it is likely that reasons for failure to 
provide information differ by race/ethnicity, and reasons for failure to provide information to 
minority and female patients (the majority of patients with LN-ESRD) are more likely to 
represent subjective assessments (e.g., “psychologically unfit”) (29). Thus, being 
appropriately and thoroughly informed of options may not be equivalent by race/ethnicity.
Similar to reported findings in the overall ESRD population (43,44), lack of insurance at the 
start of ESRD was strongly associated with less successful translation of all examined 
quality-of-care measures after adjustment for other sociodemographic and clinical factors. 
This disparity is likely at least partially related to the actual or perceived inability of 
uninsured patients to cover expenses associated with specialty care, including nephrology, 
transplant evaluation, and vascular access surgery. However, not having private insurance at 
the time of ESRD development was also associated with a lower likelihood of pre-ESRD 
nephrology care, being informed of transplant options, and waitlisting. After the first year of 
ESRD, when all treated patients have CMS coverage for ESRD services, the association of 
having no or public insurance with lower likelihood of waitlisting persisted. For example, 
LN-ESRD patients with Medicaid remained nearly 50% less likely to be wait-listed than 
LN-ESRD patients with private insurance at the start of ESRD, suggesting that these patients 
are less likely to be perceived as suitable candidates for transplant even after they gain 
equivalent access to CMS ESRD coverage. The 3-year limit on coverage for 
immunosuppressive treatment among transplant patients who qualify for Medicare based 
solely on ESRD may act as a provider deterrent to waitlisting young, uninsured, or publicly 
insured LN-ESRD patients. However, the pattern is likely not fully explained by this policy 
(45).
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Area-based socioeconomic measures of lower educational attainment and greater poverty 
were associated with inadequate pre-ESRD nephrology care and access to transplantation, 
although after adjustment for individual factors the impact was generally more modest and 
less statistically significant than that of individual race/ethnicity or insurance status. Whether 
the area-level associations represent proxy effects for individual poverty and education level 
not captured by individual race/ethnicity and insurance status or contextual effects is 
unknown without information on individual education and poverty status. After adjustment, 
the racial composition of patients’ residential area was not associated with most of these 
quality-of-care measures except transplant waitlisting over the entire followup period, 
suggesting that individual race/ethnicity, along with age, sex, insurance status, and comorbid 
conditions, may explain most differences in quality of care by residential-area racial 
composition.
Translation of most of the quality-of-care measures examined, with the exception of being 
informed of transplant options, also differed among LN-ESRD patients by US region as 
defined by ESRD Network. Even with adjustment for ESRD Network differences in age, 
sex, race/ethnicity, and insurance, LN-ESRD patients in the Northeast, and especially New 
England, had a relatively high likelihood of pre-ESRD nephrology care, transplant 
waitlisting, and permanent vascular access placement, mirroring patterns seen in the overall 
ESRD population (26,33,46–48). Patients in the Northwest similarly had a high likelihood of 
pre-ESRD care and permanent vascular access placement, but these same patients had a 
relatively low likelihood of transplant waitlisting. LN-ESRD patients in Southern California 
were generally less likely than patients in other ESRD Networks to have pre-ESRD 
nephrology care, transplant waitlisting, and permanent vascular access placement.
The inconsistency of these geographic disparities across quality measures may be the result 
of differences between ESRD Networks in resources and priorities—despite national 
programs designed to eliminate these regional differences, such as the Fistula First 
Breakthrough Initiative (32,33,49). Alternatively, the varying prevalence of LN-ESRD 
across ESRD Networks could lead to differences in provider experience and comfort with 
the care of lupus nephritis and associated ESRD, leading to differences in the translation of 
these quality-of-care measures. Of course, for ESRD Networks with small proportions of the 
overall LN-ESRD population, statistical differences may also be due to chance.
This study has several limitations. The USRDS does not capture non–Medicare-eligible 
individuals, including undocumented residents who are likely to be socioeconomically 
deprived and geographically concentrated. Also, attribution of ESRD cause on the 
CMS-2728 has unknown validity; one small validation study (50) conducted using biopsy 
samples obtained prior to 2001 suggests that sensitivity is potentially low although attributed 
causes were mostly missing, contributing to low agreement. If these validation results apply 
in the more modern era, with nearly complete data on attributed cause, our study population 
may not have captured all individuals with LN-ESRD and, if differential by 
sociodemographics, region, and/or quality of care, this could potentially bias our results. 
Provider accuracy in recording other patient variables, including race/ethnicity and insurance 
status as well as quality measures, may also be imperfect. Death may factor as a competing 
risk to analyses of time to waitlisting, although sensitivity analyses using only patients who 
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did not die during the first year suggest that the effect of this bias is likely minimal. ZCTAs 
and measures at the ZCTA level may serve as insufficient proxies for neighborhoods and for 
characteristics of the individuals within these areas, respectively. Further, more granular 
information on ethnicity and language barriers, which may be important for the 
comprehensive assessment of disparities, was not available. There also is the potential for 
selection bias due to excluded data in analyses of pre-ESRD care, since included and 
excluded patients differed on several characteristics. However, pre-ESRD care status was 
unknown in <10%, and sensitivity analyses showed that any bias was likely minimal. 
Misclassification of quality of care on the CMS-2728 is also possible, although pre-ESRD 
care appears to be accurately captured with respect to patients with preemptive transplants 
and waitlisting. Many confounding factors may instead or also serve as mediating factors, 
leading to potential overadjustment, and, as with any observational study, there is possible 
residual confounding, particularly due to provider factors such as availability of 
nephrologists and rheumatologists.
However, the study also has several powerful strengths. These include the capture of all US 
patients treated for ESRD, limited loss to followup due to universal coverage of ESRD 
services by CMS, and the provision of the Medicare eligibility form (CMS-2728)—which 
includes ESRD quality-of-care information of interest to CMS—for all treated patients.
Despite its limitations, this investigation provides a comprehensive, national snapshot of 
ESRD quality of care for US patients with LN-ESRD, overall and by patient characteristics 
and US region. The results encourage hypothesis generation and further analysis regarding 
potential barriers to improving quality of ESRD care in this population at the levels of the 
health system, ESRD Networks, providers (including rheumatologists, nephrologists, and 
transplant and vascular access surgeons), and patients. Our findings also identify potential 
specific targets with respect to inadequate translation of quality-of-care measures in this 
population (particularly, permanent vascular access placement) and the LN-ESRD patient 
subpopulations that are least likely to receive high-quality care, as assessed by these 
measures. For example, an ESRD Network–level intervention to enhance rheumatology–
nephrology partnerships aimed at improving ESRD care could be targeted to a region with a 
large population of uninsured, black LN-ESRD patients, such as the Southeast. Such efforts 
have the potential to ensure better and more equitable quality of ESRD care among patients 
with SLE.
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Selection of study populations for assessment of quality measures related to pre–end-stage 
renal disease (ESRD) nephrology care, access to transplant (informed of transplant options, 
time to placement on the kidney transplant waitlist), and presence of a permanent vascular 
access for dialysis, among US patients in whom treatment was being initiated for ESRD 
attributed to lupus nephritis (LN), July 1, 2005–September 30, 2011.
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Age-, sex-, race/ethnicity-, and insurance-adjusted probability of receipt of nephrology care 
prior to end-stage renal disease (ESRD) (A), probability of being informed of transplant 
options at the start of dialysis (B), rate of placement on the kidney transplant waitlist (C), 
and probability of a permanent vascular access used or in place at first dialysis (D), by US 
region defined according to Centers for Medicare & Medicaid Services ESRD Networks, 
among US patients in whom treatment was being initiated for ESRD attributed to lupus 
nephritis, July 1, 2005–September 30, 2011.
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Table 1
Characteristics at the time of incident ESRD in US patients in whom treatment for ESRD attributed to lupus 
nephritis was initiated between July 1, 2005 and September 30, 2011*
Patient factors
 Age, mean ± SD years (n = 6,594) 39.6 ± 15.4
 Sex (n = 6,594)
  Female 81.1
  Male 18.9
 Race/ethnicity (n = 6,594)
  White 24.7
  Black 49.7
  Hispanic 17.7
  Other 7.9
 Insurance (n = 6,594)
  Private 37.4
  Medicare/other† 18.4
  Medicaid 32.8
  None 11.5
 Smoking (n = 6,594)
  Yes 4.3
  No 95.7
 BMI, mean ± SD kg/m2 (n = 6,522) 26.9 ± 7.4
 BMI ≥35 kg/m2 (n = 6,522)
  Yes 12.6
  No 87.4
 No. of comorbidities (n = 6,594)
  0 10.9
  1 56.0
  ≥2 33.1
 Hypertension (n = 6,594)
  Yes 83.6
  No 16.4
 CVD (n = 6,594)
  Yes 18.6
  No 81.4
  Serum albumin, mean ± SD gm/dl (n = 5,201) 2.9 ± 0.8
  Serum hemoglobin, mean ± SD gm/dl (n = 6,124) 9.5 ±1.7
 ESRD Network (n = 6,549)
  1 (CT, ME, MA, NH, RI, VT) 2.5
  2 (NY) 7.5
  3 (NJ) 3.9
  4 (DE, PA) 3.5
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  5 (DC, MD, VA, WV) 5.6
  6 (GA, NC, SC) 10.3
  7 (FL) 7.0
  8 (AL, MS, TN) 6.3
  9 (IN, KY, OH) 5.1
  10 (IL) 4.6
  11 (MI, MN, ND, SD, WI) 6.2
  12 (IA, KS, MO, NE) 2.7
  13 (AR, LA, OK) 4.1
  14 (TX) 10.6
  15 (AZ, CO, NM, NV, UT, WY) 5.1
  16 (AK, ID, MT, OR, WA) 2.3
  17 (HI, Northern CA) 5.1
  18 (Southern CA) 7.6
Patient residential neighborhood (ZCTA) factors, median (IQR) %
 Black race 14.1 (3.7–41.4)
 Hispanic ethnicity 9.9 (3.4–29.9)
 Dropped out of high school 16.7 (10.1–24.4)
 Income below poverty level 16.5 (9.8–24.9)
*
Except where indicated otherwise, values are the percent of patients. ESRD = end-stage renal disease; BMI = body mass index; CVD = 
cardiovascular disease (including pericarditis); ZCTA = ZIP code tabulation area; IQR = interquartile range.
†
Includes Medicare (n = 681), VA (n = 47), and other (n = 483).
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